Drug intelligence / Profile preview

ZD03

Development stage: Phase 1
Lead developer: Shanxi Zhendong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

ZD03 is a small molecule drug developed by Shanxi Zhendong Pharmaceutical Co., Ltd. It acts as a stimulant for Nuclear factor erythroid 2-related factor 2 (Nrf2) and is being investigated for its potential in treating immune system diseases, nervous system diseases, and other conditions. Initially, it was considered for multiple sclerosis, though its current active indications are not specified.

Other names: ZD 03ZD03ZD-03

Targets

NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)

Beyond the preview

Go deeper on ZD03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZD03.

Explore the full profile